- Home
- ECOR vs UCL Comparison
ECOR vs UCL Comparison
Compare ECOR & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- UCL
- Stock Information
- Founded
- ECOR 2005
- UCL 2014
- Country
- ECOR United States
- UCL Hong Kong
- Employees
- ECOR N/A
- UCL N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- UCL Telecommunications Equipment
- Sector
- ECOR Health Care
- UCL Consumer Discretionary
- Exchange
- ECOR Nasdaq
- UCL Nasdaq
- Market Cap
- ECOR 50.1M
- UCL 47.0M
- IPO Year
- ECOR 2018
- UCL 2020
- Fundamental
- Price
- ECOR $5.04
- UCL $1.63
- Analyst Decision
- ECOR Strong Buy
- UCL
- Analyst Count
- ECOR 2
- UCL 0
- Target Price
- ECOR $25.50
- UCL N/A
- AVG Volume (30 Days)
- ECOR 182.1K
- UCL 82.0K
- Earning Date
- ECOR 05-07-2025
- UCL 05-21-2025
- Dividend Yield
- ECOR N/A
- UCL N/A
- EPS Growth
- ECOR N/A
- UCL N/A
- EPS
- ECOR N/A
- UCL 0.09
- Revenue
- ECOR $26,458,000.00
- UCL $92,256,000.00
- Revenue This Year
- ECOR $26.76
- UCL $4.93
- Revenue Next Year
- ECOR $44.87
- UCL N/A
- P/E Ratio
- ECOR N/A
- UCL $18.01
- Revenue Growth
- ECOR 41.54
- UCL 7.65
- 52 Week Low
- ECOR $4.47
- UCL $0.80
- 52 Week High
- ECOR $19.49
- UCL $3.30
- Technical
- Relative Strength Index (RSI)
- ECOR 39.64
- UCL 68.85
- Support Level
- ECOR $4.77
- UCL $1.59
- Resistance Level
- ECOR $5.49
- UCL $1.90
- Average True Range (ATR)
- ECOR 0.44
- UCL 0.14
- MACD
- ECOR 0.08
- UCL 0.04
- Stochastic Oscillator
- ECOR 41.08
- UCL 63.08
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.